PolicyMiddle East
Scancell Advances Immunotherapy Pipeline with FDA RMAT Designation and Phase 3 Trial Preparations
Scancell plc has announced significant corporate and clinical milestones, including FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its lead immunotherapy candidate iSCIB1+ in advanced melanoma. The company remains on track for its NASDAQ listing and the initiation of a global Phase 3 registrational…
Thursday, November 19, 2026